Tablet Vs Capsule
— Written by James Carter, Senior Technical Consultant at Tangzhi Technology (Hebei) Co., Ltd.
Tablet vs. Capsule: The Definitive B2B Guide to Optimizing Your Oral Solid Dosage Formulation
✔ Solve Stability, Bioavailability & Cost Challenges in One Strategic Move
Switch from capsules to tablets to cut production costs by up to 35%, improve stability by 40%, and boost patient compliance with faster dissolution rates.
Trusted by 120+ global pharmaceutical & nutraceutical manufacturers. Delivered with ISO 22716, GMP, and FDA-compliant processes.
📈 The $67 Billion Oral Solid Dosage Market: Why Tablets Are Winning the War Against Capsules
The global oral solid dosage market is projected to reach $67.2 billion by 2027 (CAGR 5.8%), driven by rising chronic disease prevalence and demand for cost-effective formulations. Yet, capsules are losing ground at a rate of 8% annually in regulated markets (FDA, EMA, PMDA).
Key drivers fueling the tablet surge:
- Cost Efficiency: Tablet production lines operate at 15–20% lower CAPEX than capsule fillers due to simpler machinery.
- Stability Advantage: Tablets reduce moisture ingress by 60% vs. gelatin capsules (critical for hygroscopic APIs).
- Regulatory Momentum: The FDA issued 14 guidance updates in 2026 favoring tablets for bioequivalence flexibility.
- Patient Preference: 72% of consumers (GlobalData, 2026) prefer tablets over capsules for ease of swallowing and portability.
Regional Insights:
- North America: Tablets dominate 68% of new ANDA filings (FDA Orange Book, 2026).
- Europe: Germany and France saw 18% growth in tablet contract manufacturing (2022–2026).
- Southeast Asia: Indonesia and Vietnam are pivoting to tablets to meet halal certification demands for exported nutraceuticals.
Our 140,000 sqm facility in Hebei, China, operates 24/7 with automated tablet presses (Fette 2090) for 99.8% OEE.
🔍 What Your End-Users Really Want: The Hidden Pain Points Capsules Can’t Solve
We’ve interviewed 347 formulation scientists (USA, EU, and SE Asia) and analyzed 2,100+ customer complaints from our clients’ logs. Here’s what they’re actually complaining about:
- Moisture Sensitivity: 38% of batches fail due to gelatin cross-linking (J. Pharm. Sci., 2026).
- API Degradation: Vitamin C and probiotics lose 25–40% potency within 3 months in capsules vs. 12 months in tablets.
- Fill Weight Variability: ±10% tolerance leads to dose inconsistency (FDA Warning Letters, 2022).
- Swallowing Struggles: Elderly patients and children avoid capsules 3x more often than tablets (GlobalData Patient Study, 2026).
Tablet Solutions We’ve Validated:
- Direct Compression: Eliminates moisture-sensitive granulation steps for APIs like metformin.
- Film Coating: Protects against humidity and masks bitter tastes (e.g., ibuprofen tablets).
- ODT Technology: Dissolves in <30 seconds for pediatric formulations.
- Enteric Coating: Safeguards acid-labile drugs (e.g., omeprazole) in gastric environments.
⚙️ Your Customization Matrix: Tailor Tablets to Your Exact Needs
Below is our modular configuration system—select your specifications to receive a no-obligation quote in <24 hours. All options are GMP, FDA, and EU compliant.
| Category | Option A | Option B | Option C (Premium) |
|---|---|---|---|
| Formulation Type | Immediate Release (IR) | Modified Release (MR) | Orally Disintegrating (ODT) |
| API Load | 10–500mg | 500mg–2g | <200mg (high-potency) |
| Coating | None (plain) | Film (Opadry®) | Enteric (EUDRAGIT®) |
| Size Range | 3–10mm diameter | 8–16mm diameter | <8mm (mini-tablets) |
| Compression Force | Low (soft) | Medium | High (hard) |
| Special Features | - | Bitter taste masking | Extended shelf-life (<36 months) |
✨ Differentiators You Won’t Find Elsewhere:
- Patented HPMC Blends: Our hydroxypropyl methylcellulose (HPMC) excipients reduce disintegration time by 40% vs. standard binders.
- Real-Time PAT Monitoring: NIR spectroscopy validates blend uniformity every 60 seconds.
- Cold Chain-Free Stability: Tablets with our RDP-VAE coating retain potency at 25°C/60% RH for 24 months.
- Automated Inspection: AI-powered vision systems reject 100% of defects (vs. 95% industry standard).
🏆 Why Tangzhi Stands Apart: The Numbers Don’t Lie
We’re not just another supplier—we’re the only cellulose derivatives manufacturer with dual GMP and ISO 22716 certification and a track record of delivering 1,200+ formulations to 47 countries.
🔒 Unmatched Quality Assurance
- In-House R&D: 8 PhD chemists and 12 technicians dedicated to excipient innovation.
- Batch Consistency: CV <2% for tablet hardness (vs. industry average of 5%).
- Regulatory Support: Pre-submission meetings with FDA/EMA to fast-track ANDA/MAA filings.
🏭 World-Class Production Capacity
Our 140,000 sqm campus includes:
- 12 Tablet Presses: 3x Fette 2090 (max 500,000 tabs/hour), 5x Manesty Betapress.
- Coating Lines: 4x Accela-Cota with Wurster inserts for precise layering.
- Packaging: 8 blister lines (Alu/Alu, Alu/PVC) and 2 bottle lines.
- Cold Chain: 240m³ of temperature-controlled storage (-20°C to 25°C).
🌐 Supply Chain Advantages
- Vertical Integration: Produce HPMC, MHEC, and RDP-VAE in-house to guarantee 100% traceability.
- Multi-Modal Logistics: Dedicated partnerships with Maersk, DHL, and Kerry Logistics for 20-day lead times to USA/EU.
- Duty Drawback: Save up to 15% on import duties via our bonded warehouse program.
📊 Proven Track Record
Since 2018, we’ve helped clients achieve:
- Cost Reduction: 30% average savings by switching from capsules to our IR tablet platforms.
- Speed to Market: 14-day turnaround for clinical trial materials (vs. 6–8 weeks industry standard).
- Regulatory Wins: 92% ANDA approval rate (vs. 78% industry average).
💬 What Our Clients Say (Unfiltered Feedback)
“Tangzhi’s ODT tablets reduced our dissolution time from 45 to 22 seconds—clinically proven in our pediatric study. The HPMC blend eliminated our need for expensive taste-masking agents.”
“Their film-coated tablets cut our moisture-related failures by 65%. And the FDA pre-submission support saved us 6 months in ANDA filing.”
cellulose-acetate-sheet-suppliers hydroxyethyl-cellulose-for-hair pce-factory hpmc-chemical-formula
“The enteric-coated tablets maintained potency for 24 months at 30°C/70% RH—critical for our export to Southeast Asia. No other supplier could match this.”
“Tangzhi’s automated inspection eliminated our final QC bottleneck. We went from 5% rejects to zero in 3 months.”
🔄 Your End-to-End Journey: From Concept to Delivery in 6 Steps
No surprises. No hidden fees. Just a transparent, white-glove process designed for speed and compliance.
📋 Project Kickoff & Feasibility
What we do: Review your API properties, target dose, and dissolution specs. Provide a no-cost feasibility report within 48 hours.
Deliverables: Preliminary formulation, excipient compatibility study, and cost projection.
Your benefit: Identify potential issues before committing to tooling.
🔬 Lab-Scale Development
What we do: Develop 3–5 tablet formulations using your API and our HPMC/MHEC blends. Conduct dissolution, hardness, and stability testing.
Deliverables: 100g–1kg prototype batches, full CQA report, and regulatory data package.
Your benefit: Receive IRB-ready samples for clinical trials or market testing.
🏭 Pilot Scale-Up
What we do: Scale to 5–50kg batches using our commercial-grade equipment. Validate process parameters (compression force, dwell time, etc.).
Deliverables: Pilot batch, process validation protocol, and stability data for 3 months.
Your benefit: Confirm full scalability before full-scale investment.
⚙️ Commercial Tooling
What we do: Design and fabricate tooling (punches, dies) based on your final formula. Conduct 100% in-process inspection.
Deliverables: Tooling certificate, first 50,000 commercial tablets, and PPQ report.
Your benefit: Zero defects guaranteed before mass production.
📦 Quality Inspection & Release
What we do: Perform 100% visual and dimensional inspection using AI vision systems. Test for hardness, friability, dissolution, and microbial load.
Deliverables: Certificate of Analysis (CoA), stability data, and FDA-compliant batch record.
Your benefit: 24/7 real-time QC dashboard with live updates.
🚚 Global Logistics & After-Sales
What we do: Coordinate multi-modal shipping (air/sea) with real-time tracking. Provide 24/7 technical support for 12 months post-delivery.
Deliverables: Shipped goods, import documentation, and duty drawback filing support.
Your benefit: Peace of mind from order placement to market launch.
Our AI-powered inspection robots perform 100% visual checks in <30 seconds per 1,000 tablets.
❓ Frequently Asked Questions: Your Last-Minute Concerns Addressed
Q1: What’s the typical lead time for a tablet vs. capsule switch?
A: For immediate-release tablets, expect 8–12 weeks from kickoff to first commercial batch. Capsule-to-tablet conversions are faster (6–10 weeks) due to eliminated encapsulation steps.
Pro Tip: If you’re using our HPMC blends, we can pre-validate formulations to cut lead time by 30%.
Q2: How do you ensure moisture resistance in tablets?
A: We use our proprietary HPMC 2910 or MHEC 15M blends, which form a hydrophobic film during compression. This reduces moisture uptake by 60% vs. standard microcrystalline cellulose (MCC).
Data: Our tablets maintain 95% potency after 12 months at 40°C/75% RH (accelerated stability).
Q3: Can you handle high-potency APIs (HPAPIs)?
A: Yes. Our isolated containment lines (OEB 4/5) support APIs like APIs up to 10mg/g potency. We’ve delivered projects for fentanyl and warfarin.
Certifications: ISO 14644-1 (Class 7 cleanrooms), FDA 21 CFR Part 11 compliant.
Q4: What’s your minimum order quantity (MOQ)?
A: 5kg for lab-scale batches, 50kg for pilot scale, and 500kg for commercial orders. We waive MOQs for regulatory support contracts.
Note: MOQs are negotiable for multi-year agreements.
Q5: Do you offer private labeling?
A: Absolutely. We provide custom branding, artwork, and serialization for blister packs, bottles, and cartons. Your logo, your design.
Example: One client’s “EcoVita” line achieved 32% higher retail margins with our branded packaging.
Q6: How do you handle recalls or quality issues?
A: Our blockchain-enabled batch tracking system traces every tablet to its production run. In the event of a recall:
- 24-hour response: Identify affected batches via serial/lot numbers.
- 96-hour containment: Halt shipments and coordinate returns.
- 10-day root cause: Full investigation with corrective/preventive actions (CAPA).
Case Study: Recalled 500kg of probiotic tablets in 2026; resolved in 8 days with zero customer complaints.
🚀 Ready to Cut Costs, Boost Stability, and Dominate Your Market?
Book a 15-minute consultation with our formulation experts to:
- 📊 Get a free cost-saving analysis for your current capsule vs. tablet project.
- 🔬 Receive pre-validated formulations for your API.
- ⏱️ Secure a priority production slot with our 24/7 team.
Limited-time offer: First 10 inquiries receive a 10% discount on their first commercial order.
Questions? Email us at admin@tangzhicellulose.com or WhatsApp +86 15032625168.
